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Abstract  46 
Context: Obesity affects the majority of women with polycystic ovary syndrome (PCOS), but 47 
previous studies are inconsistent about the prevalence of obesity and the importance of weight gain in 48 
the development of the syndrome. 49 
Objective: To explore the association between weight, weight gain, hyperandrogenism and PCOS 50 
from adolescence to late adulthood. 51 
Design: A prospective Northern Finland Birth Cohort 1966 study including 5889 females born in 52 
1966 and followed at the ages of 14, 31 and 46 years. 53 
Setting: General community.  54 
Participants: Women presenting both oligo/amenorrhea (OA) and hirsutism (H) at age 31 (N=125) or 55 
with formally diagnosed PCOS by age 46 (N=181) were compared with women without PCOS 56 
symptoms or diagnosis (n=1577).  57 
Interventions: None. 58 
Main Outcome Measures: Body-mass-index (BMI), weight change through life, waist 59 
circumference, Free Androgen Index (FAI), lipids, glucose, insulin, high-sensitivity C-reactive protein 60 
(hs-CRP), homeostatic model assessment for insulin resistance (HOMA-IR) and PCOS. 61 
Results: Women with OA+H at age 31 or diagnosis of PCOS by age 46 had the highest BMI at all 62 
ages compared with the controls. Increase of BMI between ages 14 and 31, but not between 31 and 63 
46, was greater in women with isolated OA (P=.006), OA+H (P=.001) and diagnosis of PCOS 64 
(P=.001) compared with controls. In the multivariate analysis, PCOS was significantly associated 65 
with BMI at all ages (BMI at age 31: OR=1.05 [95%CI: 1.00-1.10], FAI (OR=1.08 [95%CI: 1.03-66 
1.14]), serum levels of insulin (OR=1.05 [95%CI: 1.00-1.09]) and triglycerides (OR=1.48 [95%CI: 67 
1.08-2.03]).  68 
Conclusions:  Symptoms or diagnosis of PCOS are associated with dyslipidemia, hyperandrogenemia 69 
and significantly increased weight gain especially in early adulthood. This observation is important as 70 
it may identify a sensitive time period when weight gain plays a crucial role in the emergence of 71 
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PCOS and when preventive actions against metabolic and cardiovascular diseases should be 72 
implemented.   73 
74 
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Introduction 75 
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in premenopausal 76 
women, affecting 6-18% of reproductive aged women, depending on the source population and the 77 
diagnostic criteria (1,2). According to the Rotterdam criteria, PCOS is defined by the presence of at 78 
least two of the following three features: menstrual irregularities (oligo- or anovulation), 79 
hyperandrogenism (clinical and/or biochemical) or polycystic ovaries (PCO), after excluding other 80 
etiologies (3). PCOS is known to have multiple unfavorable effects on women’s health probably as a 81 
consequence of both hyperandrogenism (4) and insulin resistance (3,5,6). In some reported series, 82 
more than 50 percent of PCOS women are obese, and abdominal obesity and increased visceral fat 83 
distribution are common among these women (7). However, the prevalence of obesity in reported 84 
series is widely variable, probably reflecting the nature of presenting symptoms and therefore the 85 
specialist clinic to which women with PCOS may be referred. Adipose tissue, particularly visceral 86 
adipose, is an active metabolic and endocrine organ (8) and obesity significantly exacerbates all 87 
metabolic and reproductive disturbances of the syndrome (9). Excess adiposity is associated with 88 
insulin resistance and compensatory hyperinsulinemia, and leads to decreased sex-hormone binding 89 
globulin (SHBG) synthesis in the liver and excessive androgen production in the ovaries, which all 90 
contribute to an hyperandrogenic state (7). Visceral obesity increases the risk of impaired glucose 91 
tolerance and type 2 diabetes mellitus (T2DM), metabolic syndrome and cardiovascular morbidity, 92 
and that is particularly the case in women with PCOS (10-12). Previous studies have demonstrated 93 
that women with PCOS have a worse metabolic profile, including elevated triglyceride levels that are 94 
already apparent at a young age and are independent of obesity (12,13) 95 
Although it is well known that obesity exacerbates PCOS symptoms and increases the 96 
risks for T2DM and cardiovascular diseases (6), the results of previous studies have been inconsistent 97 
regarding the association between weight, weight gain and prevalence of PCOS during reproductive 98 
life. Some data suggest that the adverse outcomes are mainly related to obesity (14), whereas others 99 
claim that the syndrome per se is the most important factor (15,16). However, many studies have been 100 
underpowered and most of them are cross-sectional, using hospital-based populations and focusing 101 
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only on obese subjects and/or women seeking for infertility treatment, and thus possibly not 102 
representing the general population. If obesity is a trigger or contributing factor for the development 103 
of PCOS in patients pre-disposed to the condition, it would be expected that the dramatic worldwide 104 
increase of obesity not only in adulthood, but also in childhood and adolescence, (17,18) would result 105 
in an increasing prevalence of PCOS with its significant health and economic burdens. 106 
Our previous study from the Northern Finland Birth cohort 1966 (NFBC66) reported 107 
the association between body mass index (BMI) from birth to early adulthood and self-reported PCOS 108 
symptoms at age 31 (19). That study showed the importance of obesity in adolescence and in early 109 
adulthood, and crucial role of weight gain in early adulthood, in predicting PCOS symptoms at age 110 
31.  The present study had two main aims. First, by using the same study population as in the above 111 
mentioned study, to extend the follow-up time of the weight change in women with self-reported 112 
symptoms in early adulthood (31 years) or diagnosis of PCOS until late adulthood (46 years) and to 113 
compare it with the changes in weight over the same time period in healthy women. The second aim 114 
was to identify the most significant clinical, metabolic and hormonal indices in early adulthood (at 115 
age 31) that are associated with the diagnosis of PCOS by age 46.  116 
Materials and Methods 117 
Study subjects 118 
This study is based on a unique, large, longitudinal, prospective, population-based NFBC66, 119 
comprising all expected births in 1966 in the two northernmost provinces of Finland. The study was 120 
approved by the Ethics Committee of the Northern Ostrobothnia Hospital District. All participants 121 
provided an informed consent. 122 
In 1966, 5889 females were born alive. Enrollment in this database begun at the 24th 123 
gestational week and, so far, data collection points have been established at ages 14, 31 and 46 124 
(Figure 1). At age 14, the adolescent females (n=5455, response rate 95%) answered a postal 125 
questionnaire, with the help of their parents, including questions about weight and height. No other 126 
clinical data were collected at that age.   127 
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At age 31, a postal questionnaire was sent to 5608 women and 4523 (81%) of them 128 
answered. The questionnaire included questions about weight and height and two questions on 129 
excessive body hair and oligoamenorrhea: 1) is your menstrual cycle longer than 35 days more than 130 
twice a year and 2) do you have excessive body hair? Pregnant women, women using hormonal 131 
contraception (n=1459) and women not permitting use of their data (n=41), were excluded from the 132 
analyses. Isolated oligoamenorrhea (isOA) was reported by 11.2% (n=330) of the women who 133 
returned the questionnaire, 10.9% (n=321) reported isolated hirsutism (isH) and 4.2% (n=125) 134 
reported both of these symptoms (OA+ H) (Figure 1). The validity of this questionnaire to distinguish 135 
PCOS cases has already been shown in our previous studies from the same cohort as the women with 136 
both OA+H present the typical metabolic and hormonal profile of PCOS (20,21).  137 
In addition to this questionnaire, 4074 women living in Northern Finland or in the 138 
Helsinki metropolitan area were invited to a clinical examination. In total, 3127 (76%) women 139 
participated in a clinical examination including anthropometric measurements and blood samples for 140 
hormonal and metabolic parameters. Body mass index (BMI) was calculated as the ratio of weight 141 
(kg) and height squared (m2). Waist circumference was measured at the level midway between the 142 
lowest rib margin and the iliac crest.  143 
At age 46, a questionnaire covering several health aspects and an invitation to clinical 144 
examination was sent.  5123 women received the questionnaire and 3706 (72%) of them answered. 145 
The questionnaire included a question “Have you ever been diagnosed as having polycystic ovaries 146 
(PCO) and/or polycystic ovary syndrome (PCOS) during your life?” and 181 “yes” (considered as 147 
women with diagnosis of PCOS). The control group included all other women without any PCOS 148 
symptoms at age 31 and without diagnosis of PCOS at age 46 (n=1577). 149 
 Furthermore, 3280 women (64.0%) participated in the clinical examinations (anthropometric 150 
measurements and blood samples).  151 
The flowcharts of the study are presented in Figures 1 and 2. 152 
 Laboratory methods 153 
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At age 31, plasma glucose, and serum concentrations of total cholesterol, high-density lipoprotein 154 
cholesterol (HDL-cholesterol), low-density lipoprotein cholesterol (LDL-cholesterol), triglycerides, 155 
fasting insulin, high sensitivity C-reactive protein (hsCRP) and sex hormone binding globulin 156 
(SHBG) were all assayed as previously described (20). Serum samples for testosterone (T) were 157 
assayed using Agilent triple quadrupole 6410 LC/MS equipment with an electrospray ionization 158 
source operating in positive-ion mode (Agilent Technologies, Wilmington, DE, USA). Multiple 159 
reaction monitoring was used to quantify testosterone by using d3-testosterone, with the following 160 
transitions: m/z 289.2 to 97 and 289.2 to 109 for T and 292.2 to 97 and 292.2 to 109 for d3-161 
testosterone. The intra-assay CVs of the method were 5.3%, 1.6% and 1.2% for Tat 0.6, 6.6 and 27.7 162 
nmol/l, respectively. The interassay CVs were 5.3%, 4.2% and 1.0% for the respective concentrations. 163 
The free androgen index (FAI) was calculated by using the equation 100×T (nmol/l)/SHBG (nmol/l). 164 
To quantify the degree of insulin sensitivity, homeostasis model assessment (HOMA-IR) values were 165 
calculated using the validated calculator available at http://www.dtu.ox.ac.uk. 166 
 BMI values at ages 31 and 46 from clinical examination and postal questionnaire were 167 
combined to create a variable where clinically measured BMI was used if available and self-reported 168 
BMI was used in other cases. The data were also analyzed using only self-reported or only clinically 169 
measured BMI values, and the results were comparable. Women were categorized into BMI groups 170 
by WHO criteria for normal weight (18.5–24.9 kg/m2), overweight (25.0–29.9 kg/m2) and obese (BMI 171 
> 30.0 kg/m2) (22). 172 
Statistical methods 173 
Differences in continuous anthropometric parameters were analyzed by non-parametric Mann-174 
Whitney U-test due to the skewed distribution of variables and the differences in categorical 175 
parameters (prevalence of overweight and obesity) by Pearson’s Chi-squared test. Binary logistic 176 
regression modelling was used to determine the parameters associated with diagnosis of PCOS. We 177 
included into the multivariate binary logistic regression modelling the parameters significantly 178 
associated (P<.15) with the diagnosis of PCOS (23). FAI was used in the models as it is generally 179 
considered as the best indicator for biochemical hyperandrogenism in PCOS women (3).  HOMA-IR 180 
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was selected for the multivariate modelling in order to estimate insulin resistance, providing 181 
information from both glucose and insulin levels, and the serum levels of LDL and triglycerides were 182 
included to the models as they are the most typical lipid disorders observed in women with PCOS and  183 
linked to cardiovascular risks (6). The maximum number of variables was limited to 5 in each model. 184 
Results were reported as odds ratios (ORs) with 95% confidence intervals (95% CIs).  185 
Drop out analyses were performed to study any differences between women who only 186 
participated in the 31year study (both questionnaire and clinical examination) and the follow-up 187 
women participating in both the 31 and 46 year studies (at 31 years: both postal questionnaire and 188 
clinical examination; at 46 years: a postal questionnaire or a clinical examination or both).  189 
Statistical analyses were performed using IBM SPSS Statistics 22.0 (SPSS, Inc., 1989, 190 
2013, IBM Corp.). P-value < .05 was considered statistically significant.  191 
Results 192 
BMI and BMI change from adolescence (14 years) to late adulthood (46 years) in women with 193 
symptoms or diagnosis of PCOS  194 
 Women with self-reported OA+H at age 31 as well as women with diagnosis of PCOS 195 
by age 46 had significantly greater BMI values and greater prevalence of obesity compared with the 196 
control women at all three time-points (14, 31 and 46 years) (Table 1 and Figures 3 and 4a). These 197 
women exhibited also significantly greater abdominal obesity, measured by waist circumference, both 198 
at age 31 and 46 compared with the control women (P < .001 for both comparisons) (Table 1).  199 
Women presenting with isOA or isH at age 31 had significantly greater BMI at ages 200 
14, 31 and 46 as well as greater abdominal obesity. These women also presented more often with 201 
overweight and obesity than the control women (Table 1, Figures 3 and 4a). 202 
The weight change between ages 14 and 31 was significantly greater in women with 203 
self-reported OA+H, isOA and in women with diagnosis of PCOS by age 46 compared with the 204 
change in the control women between ages 14 and 31, but this was not the case between ages 31 and 205 
46 (Table 1, Figure 4a). Of note, women presenting with both OA+H at age 31 and the women with 206 
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both symptoms at age 31 and diagnosis of PCOS at age 46 exhibited the greatest prevalence of obesity 207 
and the most important weight gain from adolescence to late adulthood (Figures 3, 4a and 4b). 208 
Women with both isOA at age 31 and diagnosis of PCOS by age 46 had significantly 209 
greater BMI at age 14 (P = .009), 31 (P < .001) and 46 (P = .002) when compared with the women 210 
with isOA at age 31 but without diagnosis of PCOS by age 46 (Figure 4b). Women with both isH at 211 
age 31 and diagnosis of PCOS by age 46 did not significantly differ as regards of BMIs or change of 212 
BMI when compared with women with isH at age 31 and without diagnosis of PCOS by age 46. 213 
The subgroup of women without any symptoms at age 31 but with diagnosis of PCOS 214 
by age 46 (n=33) had similar BMI as the control group at ages 14 (19.15±1.9 vs. 19.08±2.4 kg/m2) 215 
and 31 (24.22±4.0 vs. 23.61±4.2 kg/m2), but their BMI was significantly greater at age 46 (28.24±5.4 216 
vs. 26.34±5.3 kg/m2, P = .028). 217 
Risk factors for reporting diagnosis of PCOS by age 46  218 
Univariate and multivariate binary logistic regression analyses were used to reveal the association of 219 
different parameters at age 31 with diagnosis of PCOS by age 46 (Table 2).  220 
Univariate analysis 221 
As expected, both isOA (OR=9.32 [95%CI: 5.75-15.12]) and isH (OR= 7.80 [95%CI: 4.69-12.97]) 222 
were the most significant indices that were associated with diagnosis of PCOS by age 46. 223 
Furthermore, BMI at all three time points, as well as waist circumference at ages 31 and 46, were also 224 
significantly associated with the diagnosis of PCOS. Of these, BMI at age 31 was the strongest 225 
predictor (highest R2-value .028). Importantly, the change in BMI between 14 and 31 years (R2-value 226 
= .013), but not between 31 and 46 years, was a significant risk factor for PCOS. Additionally, at age 227 
31 serum concentrations of T, SHBG, FAI, fasting insulin, LDL, CRP, total cholesterol, triglycerides 228 
and HOMA-IR were significantly associated with diagnosis of PCOS by age 46 (Table 2).  229 
Multivariate analysis 230 
Multivariate models were used to identify the most significant variables associated with the diagnosis 231 
of PCOS by age 46.  In the models I-III, the most significant index at age 31 associated with the 232 
diagnosis of PCOS by age 46 was FAI (Table 2, Model I- III). Serum levels of FAI, T, SHBG, insulin 233 
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and triglycerides at age 31 were significantly associated with diagnosis of PCOS independently of 234 
obesity (Table 2, Models IV-VIII). After the addition of isOA or isH to the models, all other indices 235 
lost their significance (Models I-III). BMI at age 31 remained a significant factor for PCOS together 236 
with isOA (Appendix 1, models V and VII) and SHBG remained significant together with isH 237 
(Appendix 2, model VII).  238 
Drop Out analysis 239 
Of the women who had participated in the 31year data collection, 536 did not participate in the 46 240 
year data collection and 2568 participated in both data collections. There were no significant 241 
differences between dropout (n=18) and follow-up (n=63) groups of women with self-reported OA+ 242 
H at age 31. 243 
Discussion 244 
The NFBC66 data set provides a unique opportunity to investigate the relationships between weight 245 
and change in weight from adolescence until late adulthood, PCOS symptoms, and diagnosis of 246 
PCOS. In the present analysis, weight, weight gain, serum levels of triglycerides as well as 247 
hyperandrogenemia in early adulthood emerged as significant risk factors associated with PCOS later 248 
in life. The women with isOA, both OA+H, and those with the diagnosis of PCOS, experienced 249 
significantly greater weight gain in early adulthood and through life, indicating the importance of an 250 
active screening for these symptoms as well as of the role of weight management already at 251 
adolescence. 252 
 In the present study, women with OA+H as well as those with both OA+H at age 31 253 
and diagnosis of PCOS by age 46 exhibited the greatest weight gain and also the highest prevalence of 254 
obesity throughout life, suggesting that the presence of both symptoms already in early adulthood is 255 
associated with the most severe form of the syndrome. Previous studies addressing the relationship 256 
between BMI and PCOS have been inconclusive. A study from Greece reported that BMI was similar 257 
in PCOS and referent groups (15), which may be due to the fact that the prevalence of obesity in 258 
women with PCOS shows great variation between different cultures (9), probably as a result of 259 
different lifestyle and dietary habits. In this study, obesity was present in 34% of the women with the 260 
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diagnosis of PCOS, which is greater than in Italy (14%) (24), but lower than in USA (74%) (16). 261 
Selection bias, such as the use of hospital based populations (24) or smaller sample size (15) may also 262 
explain these discrepancies.  263 
The present data analysis was able to strengthen our previous findings (19) and to 264 
extend the observations by follow-up until late adulthood, showing that weight gain in early 265 
adulthood, but not later, is significantly associated with symptoms or diagnosis of PCOS. Our results 266 
are consistent with a recent longitudinal study (25), showing that obesity and greater weight gain 267 
between ages of 20 and 30 were associated with PCOS status at age 27-30. This observation is 268 
important as it may identify a sensitive time period for the development of PCOS. All these findings 269 
also emphasize the importance of weight management in early life to avoid the onset of PCOS or 270 
attenuate its severity. The slower weight gain in late adulthood in our population may be due to 271 
improvements of diet and exercise because of a better recognition and uptake of healthy lifestyle 272 
recommendations (26), but it also might reflect a predisposition of women with PCOS for an early 273 
development of overweight/obesity. The presence not only of both symptoms, but also of isOA or 274 
isH, were the most significant factors associated with PCOS diagnosis in the multivariate analyses and 275 
with weight as well as weight gain in early adulthood. This lends emphasis to the importance of 276 
screening for these symptoms early in life.    277 
In line with previous studies (7,19,27), we found that abdominal obesity was also 278 
strongly associated with the syndrome and increased in a similar manner to BMI from early to late 279 
adulthood. One of the few studies prospectively investigating the changes of abdominal obesity in 280 
PCOS women showed that women with PCOS experienced a progressive increase in waist-hip ratio 281 
even in the absence of weight gain between ages of 20-25 and 40-45 years (28). The development of 282 
abdominal obesity may be more strongly linked to PCOS as it has been shown to contribute to 283 
hyperinsulinemia and reduce insulin sensitivity (29). In keeping with this observation, in the present 284 
study, serum insulin levels at age 31 were significantly associated with diagnosis of PCOS by age 46, 285 
independently of BMI. Of note, a recent study has suggested that the differences in insulin resistance 286 
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between PCOS and healthy women may also arise from functional differences in visceral adipose 287 
tissue between the two groups (30). 288 
Hyperandrogenemia in early adulthood was an important risk factor for diagnosis of 289 
PCOS in later life. Although the evidence is still weak, the development of PCOS has been proposed 290 
to be a consequence of an exposure to androgen excess in the intrauterine environment possibly 291 
leading to an altered programming of the fetus’s ovarian androgen production and hypothalamic-292 
pituitary function. The phenotype is further modified by mainly dietary and secondary genetic factors 293 
explaining the heterogeneous nature of the syndrome (31). Moreover, it has been proposed that lean 294 
women with PCOS have the most severe defect in the ovarian steroidogenesis and thus they do not 295 
need any exogenous factors to provoke development of PCOS, whereas women with mild defect need 296 
the contribution of obesity, abdominal obesity or insulin resistance to develop the full-blown 297 
syndrome (4,32). The present results support this hypothesis as the most significant factors associated 298 
with diagnosis of PCOS were obesity and hyperandrogenemia in early life.  In line with this, previous 299 
studies have suggested that PCOS manifested itself after a significant weight gain (7) and that obesity 300 
was strongly associated with hyperandrogenemia already in adolescence (33,34), with a higher risk of 301 
PCOS and infertility problems in later life (35).  302 
Dyslipidemia at age 31 (elevated serum levels of LDL and triglycerides) was 303 
significantly associated with the diagnosis of PCOS and the association with serum levels of 304 
triglycerides remained significant independently of BMI.  Elevated triglycerides, a well-established 305 
risk factor for the development of atherosclerosis and cardiovascular morbidity in later age, especially 306 
in women (36), has been shown to be manifest in young women with PCOS independently of obesity 307 
(13). The present observation fits also well with recent epidemiologic data indicating that PCOS has 308 
profound medical implications for the health of women by increasing the prevalence of ischemic heart 309 
and cerebrovascular diseases (37,38).  310 
The main strength of the present study is that it is a prospective population based 311 
cohort study, with the longest follow-up compared with previously published longitudinal cohort 312 
studies which have investigated the association of weight and weight gain with PCOS diagnosis 313 
14 
 
(16,25,28). Moreover, the present study consists of a research population with high participation and 314 
response rates. Dropout rates were similarly low, and there was no difference between the 315 
symptomatic dropout and follow-up subjects in metabolic and hormonal indices. Furthermore, 316 
anthropometric parameters were not merely self-reported. Limitations include self-reported symptoms 317 
and diagnosis of PCOS. Hirsutism is subjective and may be over-reported. However, we have 318 
previously shown that self-reported isolated hirsutism does correlate with increased androgen 319 
secretion in this population (20,21). The questionnaire at age 46 did not distinguish between 320 
polycystic ovaries (PCO) on ultrasound and PCOS. However, it is expected that women with only 321 
PCO morphology would exhibit milder hormonal and metabolic disorders and thus the differences 322 
between the groups would be even greater after excluding women with PCO only.  323 
Conclusions 324 
The results of this prospective population-based cohort study indicate that BMI, and especially weight 325 
gain in early adulthood, plays a crucial role for the emergence of PCOS and that women with PCOS 326 
present with an unfavorable lipid profile already in early adulthood. We were also able to show that 327 
isOA or isH, screened by a simple questionnaire at the time of early adulthood, are good predictors for 328 
the diagnosis of PCOS in later adulthood and can be used to identify the women at risk. Given the 329 
worldwide progression of the obesity epidemic, (17,18) our results suggest that an increasing 330 
prevalence of symptomatic PCOS can be expected in the future and emphasize the role of weight 331 
management during adolescence and early adulthood. Possible prevention or postponement of 332 
symptoms of PCOS would have major beneficial effects on individual’s health and quality of life and 333 
decrease significantly the health and economic burden of the syndrome.  334 
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Figure legends 447 
 448 
Figure 1. Flow chart of the study 449 
 450 
Figure 2. Description of women with diagnosis of PCOS by age 46 according to the 31-year status. 451 
 452 
Figure 3. Prevalence of overweight and obesity in the women with PCOS and PCOS related 453 
symptoms. The difference in the prevalence of overweight and obesity between different groups were 454 
analyzed by Chii squared test.* P < .05, ** P < .01 and *** P < .001 compared with the prevalence in 455 
controls in the same age group.  456 
 457 
Figure 4a and 4b. BMI at the different time points according to the presence of PCOS and PCOS 458 
related symptoms. BMI values are reported as mean ± SE at each time point and the differences 459 
between groups were analyzed using Mann-Whitney U-test. Figure 4a: * P < .05, ** P < .01 and *** 460 
P < .001 for the comparison with controls in the same age group. Figure 4b: Women with both isOA 461 
at age 31 and diagnosis of PCOS by age 46 had significantly greater BMI at age 14 (P = .009), 31 (P 462 
< .001) and 46 (P = .002) when compared with the women with isOA at age 31 but without diagnosis 463 
of PCOS by age 46. is: isolated OA: Oligoamenorrhea, H: Hirsutism. 464 
 465 
 466 
Table 1. Anthropometric profile at different time-points according to the symptoms of PCOS at age 31 and the diagnosis of PCOS by age 46. 
 
 
                                             At age 31 At age 46 
 Referentsa Only OA Only H Both Symptoms PCOS  
BMI 14 yr (kg/m2) 19.08±2.37 
(N=1338) 
19.55±2.65b
(N=260) 
19.66±2.78c 
(N=279) 
20.34±3.22d
(N=102) 
19.78±2.48c
(N=147) 
BMI 31 yr (kg/m2) 23.61±4.18 
(N=1564) 
24.79±5.26d
(N=328) 
24.28±4.63b 
(N=320) 
27.25±6.86d 
(N=121) 
25.86±5.73d
(N=169) 
BMI 46 yr (kg/m2) 26.34±5.29 
(N=1569) 
27.33±5.69c
(N=256) 
27.31±5.98b 
(N=250) 
29.13±5.99d
(N=90) 
28.49±6.51d
(N=180) 
Waist 31 yr (cm) 78.29±11.35 
(N=1118) 
80.96±14.15b
(N=221) 
79.12±11.75 
(N=219) 
88.03±17.75d
(N=81) 
83.63±15.22d
(N=135) 
Waist 46 yr (cm) 86.58±13.03 
(N=1325) 
88.93±13.74b
(N=210) 
88.99±14.11b 
(N=219) 
93.27±15.20d
(N=75) 
91.16±14.98d 
(N=154) 
Overweight 31 yr (N and %) 
 
328 (21.0%) 85 (25.9 %)c 64 (20.0%) 34 (28.1%)c 39 (23.1%)
Obese 31 yr (N and %) 104 (6.7%) 41 (12.5 %)d 37 (11.6%)c 
 
31 (25.6%)d 35 (20.7%)d
 
Overweight 46 yr (N and %) 500 (31.9%) 
 
81 (31.9 %) 95 (38.0%)b 22 (24.4%) 61 (34.1%)b
Obese 46 yr (N and %) 332 (21.2%) 68 (26.8 %)b 57 (22.8%) 
 
39 (43.3%)d 61 (34.1%)d
 
Weight gain between 14 and 31 years  
 
14.60±9.21 
(N=1343) 
16.87±11.91c
(N=269) 
14.65±9.48 
(N=283) 
19.09±12.92c 
(N=101) 
18.04±11.92c  
(N=144) 
Weight gain between 31 and 46 years 7.26±8.55 
(N=1562) 
7.24±9.58 
(N=255) 
7.68±8.54 
(N=249) 
5.15±11.40 
(N=88) 
7.29±9.98 
(N=169) 
The numbers in separate analyses vary due to non-response to some items. OA: Oligoamenorrhea, H: Hirsutism. 
a Women without any PCOS symptom (hirsutism or oligoamenorrhea) at age 31 and without diagnosis of PCOS by age 46. 
The continuous data are reported as mean ± SD and the comparison of differences between groups were performed using Mann-Whitney U-test. Categorical 
data were analyzed by Chi-squared test. b P<0.05, c P<0.01 and d P<0.001 compared with control women. 
 
Table 2. Univariate and multivariate binary logistic regression analysis for the parameters at age 31 associated with diagnosis of PCOS by age 46. 
Variables Univariate 
OR (95 % CI) 
Multivariate:  
Model I 
OR (95 % CI) 
Multivariate:  
Model II 
OR (95 % CI) 
Multivariate 
Model III 
OR (95 % CI) 
Multivariate 
Model IV 
OR (95 % CI) 
Multivariate 
Model V 
OR (95 % CI) 
Multivariate 
Model VI 
OR (95 % CI) 
Multivariate 
Model VII 
OR (95 % CI) 
Multivariate 
Model VIII 
OR (95 % CI) 
BMI 14yr 1.12 (1.05-1.19) 1.08 (0.99-1.17)        
BMI 31yr 1.09 (1.06-1.13)  1.05 (1.00-1.10)  1.07 (1.03-1.11) 1.07 (1.03-1.11) 1.06 (1.01-1.10) 1.10 (1.07-1.14) 1.07 (1.03-1.11) 
BMI 46yr 1.06 (1.04-1.09)         
Waist 31yr 1.03 (1.02-1.05)   1.02 (0.99-1.04)      
Waist 46yr 1.02 (1.01-1.04)         
Change of 
BMI 14-31yr 1.09 (1.04-1.14)         
Testosterone 
31yr 1.55 (1.24–1.93)        1.44 (1.15-1.81) 
SHBG 31yr 1.01 (1.00–1.01)       1.01 (1.00-1.01)  
FAI 31yr 1.12 (1.07–1.17) 1.07 (1.00-1.13) 1.08 (1.02-1.14) 1.13 (1.06-1.19)   1.08 (1.03-1.14)   
LDL 31yr 1.31 (1.06-1.61) 1.30 (0.98-1.73) 1.24 (0.95-1.61) 1.21 (0.92-1.60)      
HDL 31yr 0.63 (0.38-1.03)         
hsCRP 31yr 1.05 (1.01-1.10)         
Total Choles-
terol 31yr 1.30 (1.08-1.57)         
Triglycerides 
31yr 1.89 (1.43-2.52) 1.28 (0.82-2.00) 1.18 (0.77-1.82) 0.81 (0.48-1.36) 1.48(1.08-2.03)     
Insulin 31yr 
 1.09 (1.05-1.13)     1.05 (1.00-1.09)    
Glucose 31yr 0.99 (0.68-1.43)         
HOMA-IR 
31yr 1.89 (1.39-2.56) 1.07 (0.61-1.89) 0.92 (0.53-1.60) 0.99 (0.55-1.77)      
 
Parameters with a P-value <.15 (23) in the univariate binary logistic regression model and which were not significantly correlated were used in the 
multivariate binary logistic regression models. All the parameters included in the models were assessed at age 31, unless stated elsewise.  
Model I: BMI 14yr, FAI, LDL, triglycerides and HOMA-IR 
Model II: BMI, FAI, LDL, triglycerides and HOMA-IR  
Model III: Waist, FAI, LDL, triglycerides and HOMA-IR  
Model IV: BMI and triglycerides 
Model V: BMI and insulin 
Model VI: BMI and FAI 
Model VII: BMI and SHBG 
Model VIII: BMI and T  
BMI=Body-Mass-Index, T=Testosterone, FAI=Free Androgen Index, LDL=Low density lipoprotein, HOMA-IR= Homeostasis model assessment-insulin 
resistance, SHBG=Sex hormone binding globulin, HDL=High density lipoprotein and hsCRP=High sensitive C-reactive protein. 
 





Supplemental table 1. Univariate and multivariate binary logistic regression analysis for the parameters at age 31 associated with diagnosis of PCOS by age 46 
Variables Univariate 
OR (95 % CI) 
Multivariate:  
Model I 
OR (95 % CI) 
Multivariate:  
Model II 
OR (95 % CI) 
Multivariate 
Model III 
OR (95 % CI) 
Multivariate 
Model IV 
OR (95 % CI) 
Multivariate 
Model V 
OR (95 % CI) 
Multivariate 
Model VI 
OR (95 % CI) 
Multivariate 
Model VII 
OR (95 % CI) 
Multivariate 
Model VIII 
OR (95 % CI) 
isOA 31yr 9.32 (5.75-15.12) 
12.13(5.82-
25.28) 
14.12(7.45-
26.76) 
15.49(8.04-
29.83) 
10.94(6.38-
18.78) 
11.51(6.67-
19.86) 
13.34(7.18-
24.79) 
11.64(6.76-
20.06) 
13.61(7.34-
25.23) 
BMI 14yr 1.12 (1.05-1.19) 1.02 (0.89-1.17)        
BMI 31yr 1.09 (1.06-1.13)  1.05 (0.98-1.14)  1.05 (0.99-1.11) 1.07 (1.00-1.13) 1.04 (0.98-1.10) 1.06 (1.01-1.12) 1.05 (0.99-1.11) 
BMI 46yr 1.06 (1.04-1.09)         
Waist 31yr 1.03 (1.02-1.05)   1.02 (0.99-1.06)      
Waist 46yr 1.02 (1.01-1.04)         
Change of 
BMI 14-31yr 1.09 (1.04-1.14)         
Testosterone 
31yr 1.55 (1.24–1.93)        1.04 (0.73-1.47) 
SHBG 31yr 1.01 (1.00–1.01)       1.00 (0.99-1.01)  
FAI 31yr 1.12 (1.07–1.17) 1.04 (0.94-1.14) 1.03 (0.94-1.13) 1.04 (0.95-1.14)   1.03 (0.95-1.12)   
LDL 31yr 1.31 (1.06-1.61) 1.50 (0.99-2.26) 1.30 (0.90-1.87) 1.34 (0.93-1.95)      
HDL 31yr 0.63 (0.38-1.03)         
hsCRP 31yr 1.05 (1.01-1.10)         
Total Choles-
terol 31yr 1.30 (1.08-1.57)         
Triglycerides 
31yr 1.89 (1.43-2.52) 1.15 (0.55-2.43) 1.21 (0.60-2.41) 0.99 (0.46-2.12) 1.30(0.78-2.17)     
Insulin 31yr 
 1.09 (1.05-1.13)     0.99 (0.92-1.09)    
Glucose 31yr 0.99 (0.68-1.43)         
HOMA-IR 
31yr 1.89 (1.39-2.56) 0.94 (0.41-2.14) 0.67 (0.28-1.62) 0.62 (0.25-1.52)      
 
Supplemental table 2. Univariate and multivariate binary logistic regression analysis for the parameters at age 31 associated with diagnosis of PCOS by age 46 
Variables Univariate 
OR (95 % CI) 
Multivariate:  
Model I 
OR (95 % CI) 
Multivariate:  
Model II 
OR (95 % CI) 
Multivariate 
Model III 
OR (95 % CI) 
Multivariate 
Model IV 
OR (95 % CI) 
Multivariate 
Model V 
OR (95 % CI) 
Multivariate 
Model VI 
OR (95 % CI) 
Multivariate 
Model VII 
OR (95 % CI) 
Multivariate 
Model VIII 
OR (95 % CI) 
isH 31yr 7.80 (4.69-12.97) 
12.88(6.22-
26.69) 
13.09(6.74-
25.41) 
12.75(6.44-
25.22) 
10.09(5.79-
17.58 
10.47(5.98-
18.33) 
11.94(6.28-
22.70) 
10.53(5.98-
18.57) 
11.61(6.14-
21.94) 
BMI 14yr 1.12 (1.05-1.19) 1.02 (0.88-1.17)        
BMI 31yr 1.09 (1.06-1.13)  1.00 (0.91-1.09)  1.02 (0.95-1.09) 1.02 (0.96-1.09) 1.02 (0.94-1.10) 1.05 (0.99-1.11) 1.01 (0.94-1.09) 
BMI 46yr 1.06 (1.04-1.09)         
Waist 31yr 1.03 (1.02-1.05)   1.01 (0.97-1.05)      
Waist 46yr 1.02 (1.01-1.04)         
Change of 
BMI 14-31yr 1.09 (1.04-1.14)         
Testosterone 
31yr 1.55 (1.24–1.93)        1.08 (0.73-1.60) 
SHBG 31yr 1.01 (1.00–1.01)       1.01 (1.00-1.01)  
FAI 31yr 1.12 (1.07–1.17) 0.99 (0.90-1.09) 0.98 (0.89-1.08) 0.99 (0.90-1.09)   0.99 (0.90-1.09)   
LDL 31yr 1.31 (1.06-1.61) 1.21 (0.79-1.86) 1.29 (0.86-1.92) 1.22 (0.81-1.85)      
HDL 31yr 0.63 (0.38-1.03)         
hsCRP 31yr 1.05 (1.01-1.10)         
Total Choles-
terol 31yr 1.30 (1.08-1.57)         
Triglycerides 
31yr 1.89 (1.43-2.52) 1.31 (0.57-3.02) 1.44 (0.68-3.07) 1.21 (0.52-2.81) 1.49 (0.88-2.52)     
Insulin 31yr 
 1.09 (1.05-1.13)     1.04 (0.97-1.12)    
Glucose 31yr 0.99 (0.68-1.43)         
HOMA-IR 
31yr 1.89 (1.39-2.56) 1.19 (0.48-2.95) 1.18 (0.47-2.98) 1.15 (0.45-2.99)      
 
